Overview

PK and Safety of SCT510

Status:
Completed

Trial end date:
2021-07-26

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, parallel-controlled phase I clinical study comparing the pharmacokinetics, safety and immunogenicity of SCT510 with bevacizumab (Avastin®) in Chinese healthy males.

Phase:

Phase 1

Details

Lead Sponsor:

First Affiliated Hospital of Zhejiang University

Collaborator:

Sinocelltech Ltd.

Treatments:

Bevacizumab